RegulatoryCompany release

Mereo reports Q3 2026: setrusumab regulatory talks ongoing, alvelestat Phase 3 design refined with FDA

🇺🇸 Mereo BioPharma Group plc (MREO) · Mon 09 Nov 2026

Mereo BioPharma says it is still consulting regulators with Ultragenyx on a setrusumab filing path, while cash of $26.1 million is expected to last into late 2027.

Mereo BioPharma Group reported its third-quarter 2026 results on 9 November, saying discussions with regulators over a possible filing route for setrusumab in osteogenesis imperfecta are continuing. The company is working on this with its partner Ultragenyx, following the Phase 3 results announced in December 2025.

The update gives no outcome from those consultations and, based on the information available, no timeline for a submission. The company describes the talks as ongoing.

For alvelestat, Mereo and its partner Sentynl are refining the design of a Phase 3 trial in lung disease associated with alpha-1 antitrypsin deficiency (AATD). The refinement is being done through interactions with the US Food and Drug Administration. The companies aim to start the study in early 2027.

On finances, Mereo had cash of $26.1 million at 30 September. It expects this to fund operations into late 2027. Net loss for the quarter narrowed to $5.9 million.

What it means for your team

  • Setrusumab's regulatory path in osteogenesis imperfecta remains unresolved; watch for any announcement on filing strategy from Mereo and Ultragenyx.
  • Alvelestat's Phase 3 protocol is being shaped through FDA dialogue, with a start targeted for early 2027; the final design is not yet public.
  • Mereo's stated cash runway into late 2027 covers the planned alvelestat start but the update does not detail how later development would be funded.

Company's press release (SEC filing): Mereo BioPharma Group plc ↗

Article written by VigiEye from the official source (Mereo BioPharma Group plc). Claims are the company's own. AI-assisted; check the source before acting.

More Regulatory All →